De La Cruz MSD, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014;89(8):626–32.

PubMed  Google Scholar 

Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694. https://doi.org/10.3748/wjg.v22.i44.9694.

Article  PubMed  PubMed Central  Google Scholar 

Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB. 2008;10(1):58–62. https://doi.org/10.1080/13651820701883148.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun H, Ma H, Hong G, Sun H, Wang J. Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981–2010. Sci Rep. 2014;4:6747. https://doi.org/10.1038/srep06747.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in pancreatic cancer. Int J Mol Sci. 2019;20(18):4504. https://doi.org/10.3390/ijms20184504.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tan S, Li D, Zhu X. Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacother. 2020;124:109821. https://doi.org/10.1016/j.biopha.2020.109821.

Apte MV, Wilson JS, Lugea A, Pandol SJ. A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology. 2013;144(6):1210–9. https://doi.org/10.1053/j.gastro.2012.11.037.

Article  PubMed  Google Scholar 

Charmsaz S, Collins DM, Perry AS, Prencipe M. Novel strategies for cancer treatment: highlights from the 55th IACR Annual Conference. Cancers. 2019;11(8):1125. https://doi.org/10.3390/cancers11081125.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whatcott CJ, Posner RG, Von Hoff DD, Han H. Desmoplasia and chemoresistance in pancreatic cancer. In: Grippo PJ, Munshi HG, eds. Pancreatic cancer and tumor microenvironment. Transworld Research Network; 2012. http://www.ncbi.nlm.nih.gov/books/NBK98939/. Accessed 1 Jul 2022.

Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–9. https://doi.org/10.1038/ni.2035.

Article  CAS  PubMed  Google Scholar 

Saka D, Gökalp M, Piyade B, et al. Mechanisms of T-cell exhaustion in pancreatic cancer. Cancers. 2020;12(8):E2274. https://doi.org/10.3390/cancers12082274.

Article  CAS  Google Scholar 

McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55–61. https://doi.org/10.1002/jrsm.1411.

Article  PubMed  Google Scholar 

Cibrián D, Sánchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 2017;47(6):946–53. https://doi.org/10.1002/eji.201646837.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bockorny B, Semenisty V, Macarulla T, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020;26(6):878–85. https://doi.org/10.1038/s41591-020-0880-x.

Article  CAS  PubMed  Google Scholar 

Vonderheide RH, Kraynyak KA, Shields AF, et al. Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors. J Immunother Cancer. 2021;9(7):e003019. https://doi.org/10.1136/jitc-2021-003019.

Overman M, Javle M, Davis RE, et al. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer. 2020;8(1):e000587. https://doi.org/10.1136/jitc-2020-000587.

Grage-Griebenow E, Jerg E, Gorys A, et al. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Mol Oncol. 2014;8(5):982–97. https://doi.org/10.1016/j.molonc.2014.03.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seifert AM, Eymer A, Heiduk M, et al. PD-1 expression by lymph node and intratumoral regulatory T cells is associated with lymph node metastasis in pancreatic cancer. Cancers. 2020;12(10):E2756. https://doi.org/10.3390/cancers12102756.

Article  CAS  Google Scholar 

Rea IM, McNerlan SE, Alexander HD. CD69, CD25, and HLA-DR activation antigen expression on CD3+ lymphocytes and relationship to serum TNF-alpha, IFN-gamma, and sIL-2R levels in aging. Exp Gerontol. 1999;34(1):79–93. https://doi.org/10.1016/s0531-5565(98)00058-8.

Article  CAS  PubMed  Google Scholar 

Komura T, Sakai Y, Harada K, et al. Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact. Cancer Sci. 2015;106(6):672–86. https://doi.org/10.1111/cas.12663.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Wang L, Mo Q, Dong Y, Wang G, Ji A. Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients. Int J Clin Exp Pathol. 2015;8(5):5702–5708. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503155/. Accessed 2 Jul 2022.

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors - PubMed. https://pubmed.ncbi.nlm.nih.gov/27777771/. Accessed 2 Jul 2022.

Winkler MS, Rissiek A, Priefler M, et al. Human leucocyte antigen (HLA-DR) gene expression is reduced in sepsis and correlates with impaired TNFα response: a diagnostic tool for immunosuppression? PLoS ONE. 2017;12(8):e0182427. https://doi.org/10.1371/journal.pone.0182427.

Sivakumar S, Abu-Shah E, Ahern DJ, et al. Activated regulatory T-cells, dysfunctional and senescent T-cells hinder the immunity in pancreatic cancer. Cancers. 2021;13(8):1776. https://doi.org/10.3390/cancers13081776.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ullenhag GJ, Mozaffari F, Broberg M, Mellstedt H, Liljefors M. Clinical and immune effects of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer. PLoS ONE. 2017;12(1):e0169736. https://doi.org/10.1371/journal.pone.0169736.

Wattenberg MM, Herrera VM, Giannone MA, Gladney WL, Carpenter EL, Beatty GL. Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients. JCI Insight. 2021;6(5):145389. https://doi.org/10.1172/jci.insight.145389.

Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–742. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136921/. Accessed 2 Jul 2022.

Seo YD, Jiang X, Sullivan KM, et al. Mobilization of CD8+ T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(13):3934–45. https://doi.org/10.1158/1078-0432.CCR-19-0081.

Article  CAS  Google Scholar 

Cortese N, Capretti G, Barbagallo M, et al. Metabolome of pancreatic juice delineates distinct clinical profiles of pancreatic cancer and reveals a link between glucose metabolism and PD-1+ cells. Cancer Immunol Res. 2020;8(4):493–505. https://doi.org/10.1158/2326-6066.CIR-19-0403.

Article  CAS  PubMed  Google Scholar 

Ding G, Shen T, Yan C, Zhang M, Wu Z, Cao L. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer. BMC Cancer. 2019;19(1):1053. https://doi.org/10.1186/s12885-019-6145-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Immune profiling and immunotherapeutic targets in pancreatic cancer - PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867882/. Accessed 3 Jul 2022.

Zhang M, Yang J, Zhou J, et al. Prognostic values of CD38+CD101+PD1+CD8+ T Cells in Pancreatic Cancer. Immunol Invest. 2019;48(5):466–79. https://doi.org/10.1080/08820139.2019.1566356.

Article  CAS  PubMed  Google Scholar 

Bai M, Zheng Y, Liu H, Su B, Zhan Y, He H. CXCR5+ CD8+ T cells potently infiltrate pancreatic tumors and present high functionality. Exp Cell Res. 2017;361(1):39–45. https://doi.org/10.1016/j.yexcr.2017.09.039.

Article  CAS  PubMed  Google Scholar 

Frontiers | Restored CD8+PD-1+ T cells facilitate the response to anti-PD-1 for patients with pancreatic ductal adenocarcinoma | Oncology. https://www.frontiersin.org/articles/10.3389/fonc.2022.837560/full. Accessed 3 Jul 2022.

Lau SP, Klaase L, Vink M, et al. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study. Eur J Cancer Oxf Engl. 1990;2022(169):20–31. https://doi.org/10.1016/j.ejca.2022.03.015.

Article  CAS  Google Scholar 

Karamitopoulou E, Andreou A, Pahud de Mortanges A, Tinguely M, Gloor B, Perren A. PD-1/PD-L1-associated immunoarchitectural patterns stratify pancreatic cancer patients into prognostic/predictive subgroups. Cancer Immunol Res. 2021;9(12):1439–1450. https://doi.org/10.1158/2326-6066.CIR-21-0144.

Hegde A, Jayaprakash P, Couillault CA, et al. A phase I dose-escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignancies. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(11):3050–60. https://doi.org/10.1158/1078-0432.CCR-20-4118.

Article  CAS  Google Scholar 

Shindo Y, Hazama S, Suzuki N, et al. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. J Exp Clin Cancer Res CR. 2017;36:36. https://doi.org/10.1186/s13046-017-0509-1.

Article  CAS  PubMed  Google Scholar 

Knudsen ES, Vail P, Balaji U, et al. Stratification of pancreatic ductal adenocarcinoma: combinatorial genetic, stromal, and immunologic markers. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(15):4429–40. https://doi.org/10.1158/1078-0432.CCR-17-0162.

Article  CAS  Google Scholar 

Goldberg MV, Drake CG. LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol. 2011;344:269–78. https://doi.org/10.1007/82_2010_114.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hyung J, Lee H, Jin H, et al. Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX. ESMO Open. 2022;7(3):100484. https://doi.org/10.1016/j.esmoop.2022.100484.

O’Neill C, Hayat T, Hamm J, et al. A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma. Surgery. 2020;168(4):610–6. https://doi.org/10.1016/j.surg.2020.04.057.

Article  PubMed  Google Scholar 

Romero JM, Grünwald B, Jang GH, et al. A four-chemokine signature is associated with a T-cell-inflamed phenotype in primary and metastatic pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(8):1997–2010. https://doi.org/10.1158/1078-0432.CCR-19-2803.

Article  CAS  Google Scholar